CRSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRISPR Therapeutics AG (CRSP) is not an ideal buy for a beginner, long-term investor at this moment. While the company has promising technology and a strong cash position, its recent financial performance, insider selling trends, and lack of immediate trading signals suggest caution. The stock's technical indicators and options sentiment do not strongly support a bullish case either.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 71.949, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 53.071, with resistance at 57.766 and support at 48.376. Overall, the technical indicators suggest a neutral to slightly bearish outlook.
The company has a strong cash position of $2.56 billion and promising clinical trials for multiple therapies, including cardiovascular and cancer treatments. Casgevy sales are accelerating, and analysts have raised price targets in response to pipeline progress.
Insiders have increased selling by 476.16% over the last month, which could signal a lack of confidence. The company reported a significant revenue drop of -97.58% YoY in Q4 2025, and its high-cost therapies limit patient access. Additionally, there are no recent congress trading data or proprietary trading signals to support a buy decision.
In Q4 2025, revenue dropped significantly by -97.58% YoY to $864,000. However, net income improved to -$130.6 million, up 250.07% YoY, and EPS increased to -1.37, up 211.36% YoY. Gross margin remained at 100%, but the overall financial performance indicates challenges in revenue generation despite cost control.
Analysts are mixed on CRSP. Piper Sandler raised the price target to $110 with an Overweight rating, while Morgan Stanley maintains an Underweight rating with a $33 target. Other analysts have raised targets moderately, citing pipeline progress and Casgevy sales momentum. The average sentiment leans cautiously optimistic but is not overwhelmingly bullish.
